|
3M submitted two studies to the EPA regarding perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) as part of their ongoing dialogue about fluorochemicals, focusing on health effects observed in employees from their medical surveillance programs.
|
2001 |
AR226-1046
|
5bk6Z65EJXvy8gb4wa529EjrJ |
1 |
|
The document is a final report from 3M Company detailing a longitudinal analysis of serum PFOS and PFOA levels in relation to lipid and hepatic clinical chemistry test results among male employees participating in the company's fluorochemical medical surveillance program conducted in 1994/95, 1997, and 2000.
|
2001 |
AR226-1048
|
qmk6607dG4jEQ8DwYx3MoDJvj |
63 |
|
3M submitted a correction notice to the EPA regarding a TSCA Section 8(e) Supplemental Notice on sulfonate-based fluorochemicals, including an omitted study on selected fluorochemicals in the Decatur, Alabama area, and provided additional analytical reports related to blood serum and liver levels of test materials.
|
2001 |
AR226-1049
|
gbBz7K61xOnYn19kgKxZw0KjJ |
5 |
|
The document is a final report from 3M Company detailing a cross-sectional analysis of serum levels of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) among employees participating in the 2000 medical surveillance program at their Antwerp and Decatur fluorochemical manufacturing plants, focusing on potential correlations with clinical chemistry, thyroid hormone, hemat
|
2001 |
AR226-1047
|
nNNk2NzEX2Y9gdgzNz9j458o8 |
122 |
|
This document reports on a monitoring study conducted by Entrix, Inc. for 3M, which analyzed concentrations of selected fluorochemicals, including PFOS and PFOA, in surface water, sediments, clams, and fish around the 3M facility in Decatur, Alabama, revealing significant variations in PFOS levels near the facility's discharge point.
|
2001 |
AR226-1050
|
KRd9qx6KJkmj71a5GdqXoJogx |
84 |
|
The document discusses the use of liquid chromatography/tandem mass spectrometry to analyze perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) in biota and aqueous samples following a release of firefighting foam containing these perfluorinated surfactants into Etobicoke Creek, Ontario.
|
2001 |
AR226-1059
|
oqp0zeVoyOqYMoXOQ0xgZKn8 |
2 |
|
The document discusses a method developed by researchers from Oregon State University and the University of Toronto for the determination of anionic perfluorinated surfactants, specifically perfluorinated carboxylates and sulfonates, in groundwater using liquid chromatography coupled with electrospray ionization mass spectrometry (LC ESI MS), highlighting the environmental persistence of these compounds and the discontinuation of their production
|
2001 |
AR226-1060
|
NKr2J75bO89ene494vJoKG3D |
2 |
|
The document is a guide developed by the Fluoropolymer Manufacturers Group intended to provide general guidelines for the safe handling of fluoropolymer dispersions, emphasizing that it does not guarantee compliance with regulations or safe operation.
|
2001 |
AR226-1063
|
ymm99K9Xw0QqXJgwBwwrj2nxd |
21 |
|
This document is a cover page for a toxicity study (MIN 252/004312) conducted by a research laboratory, detailing compliance with Good Laboratory Practice standards and including quality assurance statements related to the study.
|
2001 |
AR226-1056
|
vmK9nMwjjNJ6zBky1dq83Lzq |
258 |
|
The document is a final report from 3M Company detailing a cross-sectional analysis of serum levels of perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) among employees participating in the 2000 medical surveillance program at their Antwerp and Decatur fluorochemical manufacturing plants, highlighting the demographics and participation rates of the employees involved.
|
2001 |
AR226-1087
|
LJ4ZReDXD8ZLqnaDmK03O3aZb |
122 |
|
The document is a final report from 3M Company detailing a longitudinal analysis of serum levels of Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) in relation to lipid and hepatic clinical chemistry test results among male employees participating in the company's fluorochemical medical surveillance program conducted in 1994/95, 1997, and
|
2001 |
AR226-1088
|
xzxzyDB05Xvq233yprqbaYpKE |
63 |
|
The document is a final summary report of an extended recovery study following a 26-week capsule toxicity study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS) conducted on Cynomolgus monkeys, sponsored by 3M and compliant with EPA Good Laboratory Practice Standards.
|
2001 |
AR226-1102
|
85dqNoVOmoovxmn0Z0dBG3G4a |
23 |
|
The document details a revised soil adsorption study for Perfluorooctanesulfonate (PFOS), indicating its purity of 97.9% and describing the methodology based on OECD 106, including soil characteristics from various locations in Minnesota and North Dakota.
|
2001 |
AR226-1107
|
dn94B0xpjXVXoDZz7qEqG3zpe |
28 |
|
A monitoring study conducted by Entrix, Inc. for 3M assessed the concentrations of selected fluorochemicals, including PFOS and PFOA, in surface water, sediments, clams, and fish in the Decatur, Alabama area, revealing that while the 3M Outfall affected water quality in Bakers Creek, no significant changes were observed at the downstream location, Fox Creek.
|
2001 |
AR226-1109
|
a42DVpQon4kjDyxg03NG9rEVB |
40 |
|
This document details a study on the bioaccumulation of perfluorooctanesulfonate (PFOS) from a 3M production lot in bluegill fish, indicating a purity of 86.9% and outlining the testing methods, conditions, and results related to PFOS exposure and its effects on the fish.
|
2001 |
AR226-1108
|
MJ2Q5yLnKXeXxBKEqvo1JvEGa |
139 |
|
The document is an annual report detailing the activities and progress of the Telomer Research Program grant at the University of Toronto, led by Scott Mabury, focusing on fluorotelomer alcohols (FTOH) research and involving multiple academic collaborators and students.
|
2001 |
AR226-1281
|
LBoL0mY2KboaXk4wDe70qN1d |
19 |
|
This document appears to be a list of various studies and reports related to fluorinated surfactants and PFOA/PFOS, including titles, types, and submission dates to the EPA.
|
2001 |
AR226-1294
|
99maYVjZr7B2RrjNBRyG1X4x7 |
1 |
|
This document is a correspondence regarding a class action lawsuit against E.I. duPont de Nemours and Company related to the contamination of drinking water in Wood County, West Virginia, with ammonium perfluorooctanoate (PFOA).
|
2001 |
AR226-1170
|
VK2m4p0XMVR6Y5nvz861qEJn4 |
4 |
|
The document reports on a range-finding study conducted by E.I. du Pont de Nemours and Company to determine dose levels for a 90-day subchronic toxicity study of 8-2 Telomer B Alcohol in rats, noting no mortality but a significant increase in striated teeth incidence related to the test substance.
|
2001 |
AR226-1339
|
rxRQp64LXQ2XXNwd3Xz6mr6de |
11 |
|
The document reports on a study conducted by Covance Laboratories to evaluate the clastogenic activity of 8-2 Alcohol in male rats, finding no significant increase in micronucleated polychromatic erythrocytes at any tested dose level.
|
2001 |
AR226-1345
|
YMLDVpJ9xnYyXgkVVOgw5y0 |
2 |
|
The document reports on a study conducted by Covance Laboratories to evaluate the mutagenic potential of purified 8-2 alcohol using Salmonella and Escherichia coli strains, finding no significant increase in reverse mutations across the tested strains.
|
2001 |
AR226-1346
|
ZJ8MvEG0R9qneGK3bvv289vMZ |
2 |
|
This document is a letter from 3M Specialty Materials dated January 18, 2001, regarding a supplemental submission related to perfluorooctanesulfonamide (PFOSA) and includes a final report on a toxicokinetic study of PFOSA in rats conducted by 3M's Strategic Toxicology Laboratory.
|
2001 |
AR226-0992
|
NG7LeMg7N8mj47d9bmj856X7b |
3 |
|
This is a letter from Taft, Stettinius & Hollister LLP, dated March 6, 2001, regarding a request for governmental action and intent to sue DuPont over C-8 releases in Wood County, West Virginia, representing the Tennant family in an ongoing lawsuit.
|
2001 |
AR226-1246
|
v1waEkjR5yRN1LGymGDrm37Vm |
957 |
|
The document is a Consent Order issued to E. I. Du Pont de Nemours and Company by the West Virginia Department of Environmental Protection and the Department of Health and Human Resources, requiring actions to assess the impact of ammonium perfluorooctanoate (C8) releases from DuPont's operations on human health and the environment.
|
2001 |
AR226-1171
|
npnMKBGZ4NzeVVBbENd0vvZa8 |
37 |
|
The document is a PowerPoint presentation summarizing EPA activities and issues related to fluorosurfactants, specifically PFOS and PFOA, presented to the Department of Defense to assist in their budget and operational planning for fire fighting activities.
|
2001 |
AR226-0996
|
15bb0eG1dgDnpx9La4a900qvE |
4 |
|
This document is a final report of an in vivo rat micronucleus assay conducted by Covance Laboratories for the Telomer Research Program Consortium, assessing the genotoxicity of a test article related to perfluorinated compounds.
|
2001 |
AR226-1198
|
zzojrxx3Oj78kEyeQ1wqrGN8B |
31 |
|
The document is a final report on a toxicity test conducted by Wildlife International, Ltd. for 3M Corporation, assessing the effects of PFOS on seedling emergence of seven plant species, completed in compliance with Good Laboratory Practice standards.
|
2001 |
AR226-1369
|
BBDwGnK9nx8n3OyBar80JxdJ |
135 |
|
This document details the analytical method validation for the determination of perfluorooctanesulfonate (PFOS) in artificial soil, conducted by Wildlife International, Ltd. for 3M Corporation, and completed on May 27, 2003, while noting compliance with Good Laboratory Practice Standards with some exceptions.
|
2001 |
AR226-1370
|
ym9zrjRZ1yaYZ26qJDGVwg9LV |
46 |
|
This document details the analytical method validation for determining perfluorooctanesulfonate (PFOS) in plant tissues, conducted by Wildlife International, Ltd. for 3M Corporation, and completed in compliance with Good Laboratory Practice Standards, although it notes an exception regarding the stability of the test substance.
|
2001 |
AR226-1371
|
rx6Bbv6y6nqJ150GN3djdKO9r |
51 |
|
DuPont expresses concerns about potentially elevated PFOA levels exceeding the 1 ppb CEG due to a new analytical technique and plans to meet with EPA Region 3 to discuss the implications and defend their findings regarding human health impacts.
|
2001 |
AR226-1680
|
p48Y3m5dXNL2dLBw6OwQ1JED |
1 |
|
This letter details allegations from a former DuPont employee regarding the company's cover-up of environmental contamination and unsafe practices related to toxic substances, including PFOA, and expresses concern for public safety and corporate misconduct.
|
2001 |
AR226-1679
|
pm9qXr3m7Dga8k3EdDgnZajmj |
3 |
|
DuPont representatives express urgent concerns to EPA Region 3 regarding the use of their CEG as a screening level for health risks associated with PFOA, while requesting a meeting to discuss their new analytical method and sampling protocol.
|
2001 |
AR226-1681
|
J3mBq9D1YBYp0pGmr8RJOGXya |
1 |
|
The document discusses the preparation of a summary on PFOA for the EPA, emphasizing that levels above DuPont's CEO limit of 1 ppb in drinking water do not constitute an emergency requiring immediate action, despite concerns about exposure from ambient air.
|
2001 |
AR226-1682
|
0qDBR5K2qxdGBnVOQ3xa4ng2k |
3 |
|
Unreadable document.
|
2001 |
AR226-1683
|
29jQZOobdGML7BeRVQy8YwMp |
1 |
|
The document discusses a communication regarding the assessment of potential off-plant impacts of PFOA, emphasizing the need to focus on chronic exposure rather than acute exposure in discussions with the West Virginia Department of Environmental Protection's Division of Air Quality.
|
2001 |
AR226-1684
|
OyyObVRBzJm2rkd67qzjZyVK |
1 |
|
The document discusses upcoming drinking water concentration tests for PFOA using a new method, indicating expected results significantly higher than previous measurements, and outlines efforts to communicate with regulators about the situation to prevent drastic actions regarding drinking water sources.
|
2001 |
AR226-1685
|
n964Z3N571bnd08YMmqXKGmRa |
1 |
|
The document discusses a meeting between DuPont and EPA Region 3 regarding PFOA, highlighting the need for recent primate study results, air monitoring data for Lubeck, and concerns about outdated analytical protocols potentially underestimating PFOA concentrations in water.
|
2001 |
AR226-1686
|
gbJKZ340zjB7rBe5y4b28kq3J |
1 |
|
The document discusses a communication between John R. Bowman and Jack S. Mandel regarding Mandel's potential involvement in PFOA-related work with DuPont, with 3M expressing no objection to his assistance as long as confidentiality is maintained.
|
2001 |
AR226-1688
|
0q0YX68mvj0YqmqXGp02Y6Vpk |
1 |
|
This document reviews the occurrence and hazards of perfluoroalkyl substances in the UK, specifically in response to 3M's decision to phase out certain fully-fluorinated alkyl products due to their severe environmental effects.
|
2001 |
AR226-1238
|
44y7y4kaQBJnKerJkqBaVY7XV |
55 |
|
The document presents a simple compartmental model developed by DuPont researchers to estimate perfluorooctanoate (PFO) blood concentrations in humans based on exposure to ammonium perfluorooctanoate (APFO) through ingestion or inhalation.
|
2001 |
AR226-1478
|
QJmkoqrkv3BRX5K97Q4XOyzyE |
10 |
|
This letter from DuPont's corporate counsel, Andrea V. Malinowski, informs the EPA that certain documents related to a lawsuit against DuPont are claimed as TSCA Confidential Business Information, while others can be made public.
|
2001 |
AR226-1245
|
5Do6aDx17b32OY47nQm2q5Mxe |
1 |
|
an acute inhalation toxicokinetic study of perfluoroctanesulfonyl fluoride (POSF) conducted by 3M, which found that while PFOS was detected in the serum of rats post-exposure, all animals tolerated the exposure without significant clinical pathology or weight loss.
|
2001 |
AR226-1729
|
Expgjk4Gx56BQ383GMEe7GNRg |
17 |
|
The document summarizes a dietary chronic definitive reproductive study on perfluorooctanesulfonate (PFOS) conducted on mallards, detailing the experimental design, treatment levels, and observations of toxicity, which led to the termination of higher concentration groups due to adverse effects.
|
2001 |
AR226-1741
|
MGdVaYzEk8JDnNNvLQDyEyNm7 |
11 |
|
The document details a study conducted by Centre Analytical Laboratories, Inc. for 3M Environmental Technology and Safety Services on the extraction of potassium perfluorooctanesulfonate (PFOS) from egg components using HPLC-Electrospray/Mass Spectrometry, which was completed in compliance with US EPA TSCA Good Laboratory Practice Standards.
|
2001 |
AR226-1740
|
X7Q7QQEpZ94nMOeD57ERzDegK |
102 |
|
The document details a study conducted by Centre Analytical Laboratories, Inc. for 3M Environmental Technology and Safety Services on the extraction of potassium perfluorooctanesulfonate (PFOS) from mallard serum and liver using HPLC-Electrospray/Mass Spectrometry, ensuring compliance with EPA Good Laboratory Practice Standards.
|
2001 |
AR226-1739
|
09z6OOveopyYb84G5L92nN3k |
104 |
|
The document is a C-8 Data Summary Report submitted by DuPont for the Washington Works facility and associated landfills, detailing the results of investigations and sampling related to perfluorinated compounds, specifically C-8, to fulfill requirements of a Multi-Media Consent Order.
|
2001 |
AR226-1503
|
KR8RZg3G9O7vdvVgXLex22NEo |
304 |
|
This laboratory report details a PFOS dietary LC50 study conducted by 3M Environmental Technology & Safety Services on northern bobwhite birds, revealing significant variability in PFOS levels in sera among individual animals while liver PFOS levels were more consistent and generally increased with dose level.
|
2001 |
AR226-1748
|
gEQMV7pxgX5qo4wKVeOZGw4DG |
16 |
|
A dietary chronic definitive reproductive study on PFOS (perfluorooctanesulfonate) was conducted on northern bobwhite quail, revealing overt signs of toxicity at higher concentrations, leading to the termination of the 150 ppm and 50 ppm treatments due to adverse effects.
|
2001 |
AR226-1752
|
2JxEDMGRbppjE5Mwd2LK2deQr |
11 |
|
The document details a study conducted by Centre Analytical Laboratories, Inc. for 3M Environmental Technology and Safety Services on the extraction of potassium perfluorooctanesulfonate (PFOS) from quail serum and liver using HPLC-Electrospray/Mass Spectrometry, which was performed in compliance with EPA Good Laboratory Practice Standards.
|
2001 |
AR226-1751
|
b52X5XEXqNQx5V8DV3X7LGwV3 |
102 |
|
The document reports on a study conducted by the Centre National de la Recherche Scientifique to investigate the atmospheric fate of fluorinated alcohols, specifically focusing on the kinetic rate constants of trifluoropropanol (TFP) and tridecafluoro-octanol (TDO) with hydroxyl radicals, as surrogates for 2-perfluoro-n-octyl ethanol (2
|
2001 |
AR226-1520
|
y8Kq1wBM42ywkGVe5Y2ZKe4d |
3 |
|
The document is a final report of a reproduction study on PFOS conducted on the Northern Bobwhite by Wildlife International, Ltd. for 3M Corporation, which was completed on August 20, 2003, and adhered to Good Laboratory Practice standards with some exceptions noted regarding analytical reports.
|
2001 |
AR226-1753
|
4a4XBYZLVvpEOV2p3n6G8RaoR |
196 |
|
DuPont's January 25, 2001 letter to the EPA reports the results of blood serum tests for workers potentially exposed to Ammonium Perfluorooctanoate (APFO), revealing a maximum concentration of 9.0 ppm and a mean concentration of 1.53 ppm, with an investigation ongoing into elevated results from a specific job group.
|
2001 |
AR226-1556
|
JNVVQLE2pdOJ0ykwDBmK9Ojq2 |
14 |
|
The document is a letter from the EPA to DuPont Haskell Laboratory requesting clarification on why the results of human blood serum tests for ammonium perfluorooctanoate (PFOA) were submitted as voluntary rather than under TSCA Section 8(e), given potential human health hazard concerns.
|
2001 |
AR226-1557
|
YrdrQQ07kz5O73KZjMOoOOaJN |
1 |
|
The document is a letter from DuPont Haskell Laboratory responding to an EPA request for exposure and use information regarding PFOA, stating that no adverse health effects have been found among exposed employees, and referencing similar findings from studies by 3M Company.
|
2001 |
AR226-1558
|
LgRwY35w4aD9xmmOprkZX2jmd |
2 |
|
The document is a correspondence from the EPA requesting DuPont Haskell Laboratory to provide the complete data set of blood concentrations related to Ammonium Perfluorooctanoate (AFPO) as summarized in their report, following a previous inquiry.
|
2001 |
AR226-1559
|
OJJ873Ewaw8epELn35myXR9mw |
1 |
|
This document from DuPont Haskell Laboratory provides a corrected dataset of blood concentrations of Ammonium Perfluorooctanoate (APFO) in employees potentially exposed to the substance, addressing errors found in a previous report and including data from 1984 to 1995.
|
2001 |
AR226-1560
|
xdeEwMmr4NrY8N8RRxDqnX7zE |
4 |
|
The document is a peer review of DuPont's use and exposure to perfluorooctanoic acid (PFOA) in their fluoropolymer manufacturing processes, focusing on mass balance assessments and emissions related to their production sites worldwide.
|
2001 |
AR226-1667
|
wqEgja1yyBmMO5BpDoKy3NBmo |
25 |
|
The document discusses the results of whole-body exposures of rats to PTFE fumes, indicating that while most rats showed signs of high toxicity, one was a non-responder and another had a low response, with suggestions for improving exposure methodologies for future studies.
|
2001 |
AR226-1668
|
bX7XBE0g9BrJq3Qyy4rxV05y |
3 |
|
The document discusses concerns raised by an engineer regarding the poor recovery rate (25%) of the analytical technique used to measure surfactants, including PFOA, at Parkersburg, indicating that previously reported results may be significantly underestimated and could exceed the safe drinking water level of 1 ppb.
|
2001 |
AR226-1677
|
MGOboEMGGGrEK6NqB84Vr7967 |
1 |
|
The EPA is requesting additional information from 3M regarding the composition of their perfluoroalkyl submissions, specifically clarifying the identity of FC-95 and the confidentiality claims for other perfluoroalkyl sulfonates, as well as the identity of a perfluoroalkyl alcohol tested in a rat teratology study.
|
2000 |
AR226-0543
|
44NZBwjyV8o0ye3r1qZkYg5dR |
2 |
|
This document is a response from 3M to the EPA regarding additional information on their perfluoroalkyl submissions, specifically addressing the composition of potassium perfluorooctane sulfonate in test material FC-95 and toxicology studies involving a mixture of perfluoroalkyl alcohols.
|
2000 |
AR226-0544
|
KRjz5MxL8RN2G0m6dOrab50Q |
1 |
|
3M submitted a white paper titled "Sulfonated Perfluorochemicals in the Environment: Sources, Dispersion, Fate and Effects" as a supplemental notice regarding sulfonate-based fluorochemicals to the EPA under TSCA 8(e).
|
2000 |
AR226-0545
|
EkR4zwdN06nRDrLeG7J26Ng4 |
1 |
|
This document is a notification from 3M to the EPA regarding the submission of final reports for two-generation rat reproduction studies on N-Ethyl Perfluorooctyl Sulfonamido Ethanol and Perfluorooctane Sulfonate (PFOS) under TSCA 8(e).
|
2000 |
AR226-0551
|
vVgYJjQk6BeG5y5wGB25qbae8 |
1 |
|
The document outlines a planned one-generation reproduction study of perfluorooctane sulfonate (PFOS) in rats, detailing the study objectives, design, dosing groups, and administration procedures to gather pharmacokinetic data on PFOS in pregnant rats and their offspring.
|
2000 |
AR226-0192
|
2qX42Kj45GV8z7bLB0jRrbB2N |
5 |
|
The document is a final report on a combined oral fertility, developmental, and perinatal/postnatal reproduction toxicity study of PFOS conducted in rats, detailing the study's methods, results, and conclusions.
|
2000 |
AR226-0554
|
p2Rg08GRGXbBqkLVN22kjYXyw |
247 |
|
This document outlines a draft study protocol for a one-generation reproduction study of PFOS in female Harlan CD rats, aiming to investigate the potential protective effects of mevalonic acid and cholesterol against adverse maternal and fetal outcomes observed in a previous study, while also refining the no observed effect level (NOEL).
|
2000 |
AR226-0193
|
eEOGxvMK5MDMMwObnaeBov1m |
5 |
|
The document provides data from pre-1976 environmental studies conducted by 3M on the acute toxicity of perfluorooctanesulfonate (PFOS) ammonium salt (FC-93) to fathead minnows, including summaries and results from various tests performed in 1974.
|
2000 |
AR226-0194
|
2jvoDQrZ84y4kDy2jgYBpq13p |
11 |
|
The document lists various acute toxicity studies conducted by Biosearch Inc. and Riker Laboratories on perfluorooctane sulfonate (PFOS) and related compounds, detailing the test subjects, methodologies, and dates of the studies.
|
2000 |
AR226-0197
|
da94oEkRx3J6pxJoyj84JDR8G |
2 |
|
This document is an attachment to a letter from May 4, 2000, summarizing published studies on perfluorooctanesulfonates (PFOS) and perfluorooctanoic acid (PFOA), including various environmental and toxicological research findings.
|
2000 |
AR226-0198
|
p6XdXeGndNY1kpmrnL6bXLLE |
2 |
|
3M is providing the EPA with voluntary information regarding various perfluorooctylsulfonate (PFOS) salts, including their chemical designations and applications, as part of ongoing discussions about fluorochemistry.
|
2000 |
AR226-0200
|
k6Ew1mvYEXe9EJJLdNN0ewQQV |
3 |
|
This is a letter from Latham & Watkins to Dr. Charles Auer at the EPA, enclosing an analytical report from 3M's environmental monitoring program regarding biosphere sampling and analysis of perfluorinated materials, dated May 10, 2000.
|
2000 |
AR226-0201
|
MGXDbeX9Dyj548bZgDgXpQjak |
2 |
|
3M is providing supplemental information to the EPA regarding perfluorooctane sulfonates (PFOS), including executive summaries and a summary of a 26-week toxicity study in cynomolgus monkeys, to complete their previous submission.
|
2000 |
AR226-0203
|
Edb7kjbLNLBe0dVYx9QbdZMY4 |
8 |
|
3M is providing the EPA with additional voluntary information on perfluorooctane sulfonates and related compounds, including various CAS numbers, as part of ongoing discussions regarding fluorochemistry.
|
2000 |
AR226-0204
|
VekZqa6gN3Vkm8JwO3mzB9Zw |
51 |
|
The document contains a summary of acute toxicity studies on perfluorooctane sulfonate-related compounds, specifically PFOSAA, conducted by Biosearch, Inc. and Riker Laboratories for 3M, detailing various toxicity tests performed on rats and rabbits between 1978 and 1982.
|
2000 |
AR226-0216
|
yrpz3voZm23GdXrgJnRGEN5nE |
5 |
|
This final report details a pharmacokinetic study conducted by 3M on the test substance FC-129 (T-6054), which found that perfluorooctanesulfonate levels increased in rabbit liver samples 48 hours post intravenous dosing, indicating its potential as a marker for assessing dermal absorption.
|
2000 |
AR226-0226
|
n96BRoevrz5vGMQRNzGQnx53w |
96 |
|
The document contains attachments related to studies and information on perfluorooctane sulfonate (PFOS) and other perfluorinated compounds, including acute toxicity and genotoxicity studies conducted by Hazelton Laboratories America, Inc. for 3M, detailing various toxicity assessments in rabbits and rats.
|
2000 |
AR226-0228
|
rpoDazYwdJbxkGJ68ELLKXb77 |
17 |
|
This final report from 3M Environmental Laboratory details a single-dose dermal absorption and toxicity study of the perfluorinated compounds FC-129 (T-6051 and T-6054) in rabbits, finding that approximately 0.2% of the highest dose (12.8 mg/kg) was absorbed into the liver after 28 days.
|
2000 |
AR226-0225
|
JrxkbMbe9LrOYNVzV3Kk4rZjK |
151 |
|
The document is a correspondence from DuPont Haskell Laboratory to the EPA, providing summaries of studies conducted on Ammonium Perfluorooctanoate and Perfluorononanoate.
|
2000 |
AR226-0573
|
031Z6oX1XzQgbRBeyN7wK3Yk |
1 |
|
3M is submitting completed "Use and Exposure Information Profiles" (UEIPs) for various perfluorooctane sulfonate-related compounds to the EPA, ensuring the accuracy of industrial hygiene and release information.
|
2000 |
AR226-0575
|
3JB7JYg5GGOeab4ZQ8RjNmZQy |
3 |
|
3M is providing the EPA with comprehensive information on perfluorooctane sulfonates (PFOS) and related compounds, including health effects studies, reproductive studies, and environmental science data, as part of a voluntary effort to enhance regulatory understanding.
|
2000 |
AR226-0587
|
6bvdqyxyR2xOBLBB7xVM9DV86 |
3 |
|
3M is phasing out the manufacture of products based on perfluorooctanyl chemistry, including perfluorooctanoic acid (PFOA), due to environmental concerns and has submitted a detailed plan to the EPA outlining this transition.
|
2000 |
AR226-0588
|
pe9ZKNYoeJGbg3mdwa5pMmVBa |
11 |
|
This letter from 3M to the EPA discusses the company's response to a request for additional information regarding ongoing studies related to perfluorinated compounds, specifically indicating that certain study protocols and plans were provided, while some studies, including phytotoxicity, are still in development.
|
2000 |
AR226-0593
|
vy2jekNbLE9Bx2NMRwV2XZaZY |
2 |
|
3M submitted a "Use and Exposure Information Profile" for perfluorooctanoic acid and salts to the EPA, detailing their industrial hygiene program and exposure assessment methods used in their production facilities.
|
2000 |
AR226-0594
|
DGnZbMQYNanwQdM4RxXyVZE0o |
2 |
|
The document provides a voluntary use and exposure information profile for Perfluorooctanoic Acid (PFOA) and its salts, detailing production processes by 3M Company, including the synthesis via the Simons Electro Chemical Fluorination process and the estimated annual distribution amounts.
|
2000 |
AR226-0595
|
e7eDwJDK90RdD5Y90LgGGerrg |
28 |
|
This document from DuPont provides a summary of their U.S. uses of Ammonium Perfluorooctanoate (APFO), indicating that they do not manufacture it, that most of it is removed from products before sale, and that extensive industrial hygiene data show worker exposures are significantly below the ACGIH TLV.
|
2000 |
AR226-0598
|
kmxRb7j94jgZmNEVZGNmvmgvy |
2 |
|
3M is confirming meetings with the US EPA to present its phase-out plan for perfluorooctyl-based chemistries and discuss alternative chemistries, including perfluorobutane sulfonyl fluoride, scheduled for June 20th and June 22nd, 2000.
|
2000 |
AR226-0597
|
2RQRzJaNDEJLg8xQy4amEnMqb |
2 |
|
3M has submitted a detailed phase-out plan to the EPA for products based on perfluorooctanesulfonyl fluoride (POSF), indicating that production will be substantially discontinued by the end of 2000, while also noting that perfluorooctanoic acid (PFOA) will be addressed separately.
|
2000 |
AR226-0600
|
aDx4ZXmqbv0w6napEX8qrdm09 |
11 |
|
DuPont's correspondence outlines their non-manufacture of PFOS and PFOA, their use of PFOA as a surfactant in fluoropolymer production, and their commitment to provide the EPA with toxicity testing and exposure information regarding these perfluorinated compounds by May 26, 2000.
|
2000 |
AR226-0604
|
JrZdVkOYJjLke4JKGOdrLn1k2 |
1 |
|
The document is an email from Charles Auer of the EPA to Gerald Kennedy of DuPont, discussing a request for an extension on the submission date for exposure information on ammonium PFOA, with a new proposed deadline of June 23, 2000, while acknowledging the need for timely submission of toxicity information on PFOS and PFOA.
|
2000 |
AR226-0605
|
rpggpnm2xavJ8eJg6LQ2VD7vq |
1 |
|
This is a letter from DuPont Haskell Laboratory for Toxicology and Industrial Medicine, dated July 6, 2000, confirming the attendance of representatives from various companies at a meeting scheduled for July 7.
|
2000 |
AR226-0606
|
vVZq0bKVvBbEZajXaLVZdk7NY |
1 |
|
This document is a note from the EPA regarding 3M's response to missing reports related to ongoing environmental studies on perfluorooctanesulfonates (PFOS), confirming the status of various studies including biodegradation and phytotoxicity.
|
2000 |
AR226-0609
|
4aebgLwKwYgkaM6qaLVOEZBOG |
6 |
|
3M submitted a TSCA Section 8(e) report to the EPA indicating that new data from their study on retired perfluorochemical production workers suggest the half-life of perfluorooctane sulfonate (PFOS) in human serum is approximately 270 days, significantly lower than the previously estimated range of 1000-1500 days.
|
2000 |
AR226-0610
|
pBEeKnjYVKrV93b8D87z7nXG7 |
2 |
|
This interim report from 3M Company discusses the determination of serum half-lives for perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) in retired fluorochemical production employees, indicating that PFOS has a half-life significantly lower than previously estimated and that PFOA's half-life is approximately one year.
|
2000 |
AR226-0611
|
v1w69VxjE08VvXaznEpOyk6XR |
9 |
|
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding N-Methyl Perfluorooctanesulfonamido Ethanol (N-MeFOSE), indicating that a 13-week dietary study in rats showed liver effects and reduced body weights at higher doses, while no significant effects were observed at the low dose of 3ppm.
|
2000 |
AR226-0614
|
RjgXX85pkjOxk0jb6BwDZZB0k |
2 |
|
The document is a submission from 3M to the EPA, dated July 12, 2000, providing a CD containing information on perfluorooctane sulfonates and related compounds, including an extensive index for document access and noting that no confidential documents are included.
|
2000 |
AR226-0612
|
MgBgLwBKwzZM3Mg9xYxGKBgL |
45 |
|
The document contains attachments to a letter discussing various acute toxicity studies and genotoxicity tests related to perfluorooctane sulfonate (PFOS) and its derivatives, specifically detailing findings from Riker Laboratories and Coming Hazelton Inc. on compounds such as N-ethyl perfluorooctanesulfonamide (N-EtFOSA).
|
2000 |
AR226-0236
|
ea9zvaQYwbZ5RgL0jRVv5Qoq |
15 |
|
This document is a final report from 3M Environmental Laboratory detailing a pharmacokinetic study of the perfluorinated compound FC-120 (T-6052) in rabbits, which found detectable levels of organic fluorine in liver samples only at higher doses.
|
2000 |
AR226-0235
|
3QVry6zDoR9JBYzbQb0XknzrE |
143 |
|
This letter discusses 3M's announcement to withdraw certain PFOS-related products from the market by the end of 2000, while requesting the inclusion of imaging material uses on a "critical use list" for continued production, and expresses a willingness to collaborate with the EPA on finding suitable replacements and addressing interim use issues.
|
2000 |
AR226-0617
|
wqoygz0Ek6KgMX9Qp4Br1314o |
1 |
|
Dynax Corporation's letter to the EPA discusses the phase-out of 3M's AFFF agents containing PFOS and PFOA, expressing disagreement with 3M's request for an extension of the phase-out deadline, while highlighting that alternative fluorochemicals produced by other manufacturers do not contain these harmful substances.
|
2000 |
AR226-0618
|
EvnwXGKzkdnKDvnk5vYgE36eg |
6 |
|
The document discusses the environmental and health concerns associated with Perfluorooctyl Sulfonate (PFOS), produced primarily by 3M Company, highlighting its persistence, bioaccumulation, and toxicity, as well as its widespread presence in the blood of the general US population and wildlife.
|
2000 |
AR226-0619
|
82nn78Br4pRopGMZpbDXDzVpm |
17 |